Breaking Finance News

Accuray Incorporated (NASDAQ:ARAY) has been downgraded to Sell in a report by Zacks Investment Research today.

Zacks Investment Research has downgraded Accuray Incorporated (NASDAQ:ARAY) to Sell in a statement released on 5/16/2017.

Having a price of $4.07, Accuray Incorporated (NASDAQ:ARAY) traded -2.41% lower on the day. The last closing price is down -18.98% from the 200-day moving average, compared to the S&P 500 which has increased 0.02% over the same time period. The company has recorded a 50-day moving average of $4.57 and a 200-day moving average of $5.00. 496,809 shares of Accuray Incorporated were exchanged, down from an average trading volume of 877,879

See Chart Below

Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated has a with a one year low of $4.05 and a one year high of $6.39 ARAY’s total market value is presently $0.

More About Accuray Incorporated (NASDAQ:ARAY)

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *